{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:07:28Z","timestamp":1793862448558,"version":"4.6.1"},"reference-count":31,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: Angiotensin II is a peptide hormone vasopressor that activates angiotensin type 1 (AT1) receptors leading to vasoconstriction, the augmentation of arterial blood pressure (ABP), and organ perfusion. Angiotensin II was found to increase the ABP in catecholamine-refractory vasodilatory shock. Whether this effect improves the chances of survival or not remains inconclusive. Therefore, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety of angiotensin II in vasoplegic shock. Objectives: To evaluate the clinical significance of angiotensin II effects in vasoplegic shock concerning the hemodynamic impact, mortality outcomes, and side effects. Methods: Following PRISMA guidelines, we searched PubMed and EMBASE for experimental and observational studies published in English exploring the clinical outcomes of angiotensin II use in vasodilatory shock till 1 July 2024. Two independent authors assessed the quality and risk of bias of the included studies. A random effect model (Mantel\u2013Haenszel) was used to combine data. The primary outcome was in-hospital mortality associated with angiotensin II use in comparison to standard therapy, while the secondary outcomes were mean arterial pressure (MAP) change, multi-organ failure (MOF), and the incidence of atrial fibrillation (AF). The Q test and I2 were used to examine heterogeneity, with I2 &gt; 50% indicating marked heterogeneity. Results: A total of eight studies (n = 974) comparing angiotensin II to standard therapy in vasoplegic shock were included in the systematic review, with three studies comprising 461 patients included in the final analysis of the primary outcome. Only one study evaluated the use of angiotensin II as a primary vasopressor, while the rest reported angiotensin II use in catecholamine-refractory vasodilatory shock. Overall, angiotensin II use was associated with similar in-hospital mortality compared to standard therapy (risk ratio [RR] = 0.83; 95% CI, 0.68\u20131.02, I2 = 0%). Likewise, there was no difference in MOF and AF (MOF: RR = 1.01; 95% CI, 0.61\u20131.65, I2 = 0%; AF: RR = 1.27; 95% CI, 0.38\u20134.23, I2 = 5%). However, angiotensin II use demonstrated a significant MAP increase (mean difference = \u22129.60; 95% CI, \u22129.71, \u22129.49, I2 = 0%). Conclusions: In vasodilatory shock, angiotensin II use demonstrated comparable in-hospital mortality compared to standard therapy. Nevertheless, it resulted in significant MAP change, which may encourage clinicians to use it in cases of profound hypotension.<\/jats:p>","DOI":"10.3390\/life14091085","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T08:01:47Z","timestamp":1724918507000},"page":"1085","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Outcomes of Angiotensin II Therapy in Vasoplegic Shock: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6918-7350","authenticated-orcid":false,"given":"Ans","family":"Alamami","sequence":"first","affiliation":[{"name":"Medical Intensive Care, Department of Medicine, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-0184","authenticated-orcid":false,"given":"Alaa","family":"Rahhal","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Heart Hospital, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bara","family":"Alqudah","sequence":"additional","affiliation":[{"name":"Medical Intensive Care, Department of Medicine, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5046-2903","authenticated-orcid":false,"given":"Ahmed","family":"Shebani","sequence":"additional","affiliation":[{"name":"Medical Intensive Care, Department of Medicine, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelkarim","family":"Alammora","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4769-2254","authenticated-orcid":false,"given":"Hashim","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8560-2745","authenticated-orcid":false,"given":"Amr S.","family":"Omar","sequence":"additional","affiliation":[{"name":"Cardiac ICU, Department of Cardiothoracic Surgery, Heart Hospital, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-0484","authenticated-orcid":false,"given":"Ahmed Labib","family":"Shehatta","sequence":"additional","affiliation":[{"name":"Medical Intensive Care, Department of Medicine, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMra1208943","article-title":"Circulatory Shock","volume":"369","author":"Vincent","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1053\/j.jvca.2017.10.032","article-title":"Vasoplegia After Cardiovascular Procedures\u2014Pathophysiology and Targeted Therapy","volume":"32","author":"Shaefi","year":"2018","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/j.semtcvs.2010.09.007","article-title":"Vasoplegia During Cardiac Surgery: Current Concepts and Management","volume":"22","author":"Fischer","year":"2010","journal-title":"Semin. Thorac. Cardiovasc. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJMoa010307","article-title":"Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock","volume":"345","author":"Rivers","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"The PRISM Investigators (2017). Early, Goal-Directed Therapy for Septic Shock\u2014A Patient-Level Meta-Analysis. N. Engl. J. Med., 376, 2223\u20132234.","DOI":"10.1056\/NEJMoa1701380"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00134-015-3822-1","article-title":"A systematic review and meta-analysis of early goal-directed therapy for septic shock: The ARISE, ProCESS and ProMISe Investigators","volume":"41","author":"Angus","year":"2015","journal-title":"Intensive Care Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Izumi, Y., and Iwao, H. (2013). Angiotensin II Peptides. Handbook of Biologically Active Peptides, Academic Press.","DOI":"10.1016\/B978-0-12-385095-9.00186-X"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the Treatment of Vasodilatory Shock","volume":"377","author":"Khanna","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101412","DOI":"10.1016\/j.cpcardiol.2022.101412","article-title":"Effectiveness of Sacubitril\/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis","volume":"48","author":"Rahhal","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101183","DOI":"10.1016\/j.blre.2024.101183","article-title":"The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis","volume":"65","author":"Abdu","year":"2024","journal-title":"Blood Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.jvca.2020.08.001","article-title":"Treatment with Angiotensin II Is Associated with Rapid Blood Pressure Response and Vasopressor Sparing in Patients with Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Study","volume":"35","author":"Klijian","year":"2021","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s13054-014-0534-9","article-title":"Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): A pilot study","volume":"18","author":"Chawla","year":"2014","journal-title":"Crit. Care"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.chest.2020.08.2074","article-title":"Angiotensin II Infusion for Shock","volume":"159","author":"Wieruszewski","year":"2021","journal-title":"Chest"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/08850666221145864","article-title":"Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support","volume":"38","author":"Wieruszewski","year":"2023","journal-title":"J. Intensive Care Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/SHK.0000000000002109","article-title":"A pilot study of Angiotensin II as primary vasopressor in critically ill adults with vasodilatory hypotension: The aramis study","volume":"59","author":"See","year":"2023","journal-title":"Shock"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0885066620972943","article-title":"A Multicenter Observational Cohort Study of Angiotensin II in Shock","volume":"37","author":"Smith","year":"2022","journal-title":"J. Intensive Care Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13054-020-02928-0","article-title":"Angiotensin II infusion in COVID-19-associated vasodilatory shock: A case series","volume":"24","author":"Zangrillo","year":"2020","journal-title":"Crit. Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13613-024-01325-y","article-title":"Impaired angiotensin II signaling in septic shock","volume":"14","author":"Picod","year":"2024","journal-title":"Ann. Intensive Care"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s13054-023-04739-5","article-title":"The alternative renin\u2013angiotensin system in critically ill patients: Pathophysiology and therapeutic implications","volume":"27","author":"Garcia","year":"2023","journal-title":"Crit. Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1164\/rccm.201806-1034OC","article-title":"Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial","volume":"199","author":"Permpikul","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13054-022-04161-3","article-title":"Myocardial effects of angiotensin II compared to norepinephrine in an animal model of septic shock","volume":"26","author":"Garcia","year":"2022","journal-title":"Crit. Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12967-022-03842-5","article-title":"Angiotensin-(1\u20137) ameliorates sepsis-induced cardiomyopathy by alleviating inflammatory response and mitochondrial damage through the NF-\u03baB and MAPK pathways","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e860","DOI":"10.1002\/iid3.860","article-title":"Inflammatory mechanisms and intervention strategies for sepsis-induced myocardial dysfunction","volume":"11","author":"Nong","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/CCM.0000000000005721","article-title":"Mortality As a Measure of Treatment Effect in Clinical Trials Recruiting Critically Ill Patients","volume":"51","author":"Friedrich","year":"2023","journal-title":"Crit. Care Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s44158-024-00186-y","article-title":"The use of angiotensin II for the management of distributive shock: Expert consensus statements","volume":"4","author":"Landoni","year":"2024","journal-title":"J. Anesth. Analg. Crit. Care"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/9\/1085\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:44:59Z","timestamp":1760111099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/9\/1085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["life14091085"],"URL":"https:\/\/doi.org\/10.3390\/life14091085","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]}}}